Gut microbiota, FMT plus ICI trial, NSCLC, melanoma, Canada
216 fecal samples from adult NSCLC and melanoma patients in Quebec and Ontario, Canada, profiled by shotgun metagenomics across timepoints before and after fecal microbiota transplant combined with immune checkpoint inhibitor therapy (phase 2 intervention trial). machine-written summary
216 samples · 216 runs · CA · Adult · 2025 · 8.03 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 1,903 sample values (collection date, country, health condition, health condition detail, intervention, latitude, location region, longitude) |
| ○ Abstract / description | read; no usable statement |
| ○ Full text | read; no usable statement or table · PMC13099432 |
| ✓ Supplementary tables | 35 sample values (age, bmi, sex) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin Faecal microbiota transplantation design single_arm_before_after · population other_cancer · Healthy donor FMT (oral capsules) plus anti-PD-1 ± anti-CTLA-4
“received a single FMT via oral capsules” — abstract:41606121 (study level; per-sample arms are in the intervention column below)
longitudinalFMT donor → recipient — not resolved
40 of 41 people sampled more than once (214 samples; median 5, up to 8 per person) · follow-up median 14 mo (max 2.2 y) · median interval between samples 34 d (time from collection dates). Schedule stated by the source: “Before FMT (baseline), then 1 week, 1 month, 2, 3, 6, 9 months post-FMT during ICI therapy”.
Each row is one person (36 shown of 40); dots are samples at days since that person's first sample.
FMT donor-recipient design: patients received single healthy donor FMT; no family/household structure stated among patients.
Genera, mean relative abundance over 203 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 216 | 100% | ||||
| country | 216 | 100% | 216 | |||
| health_condition | 89 | 41% | 89 | |||
| subject_id | 215 | 100% | 215 | |||
| collection_date | 216 | 100% | 216 | |||
| detailed_location | 216 | 100% | ||||
| latitude | 216 | 100% | 216 | |||
| location_region | 216 | 100% | 216 | |||
| longitude | 216 | 100% | 216 | |||
| timepoint_label | 216 | 100% | 216 | |||
| intervention | 214 | 99% | 214 | |||
| health_condition_detail | 89 | 41% | 89 | |||
| sex | 33 | 15% | 33 | |||
| age_at_collection_days | 1 | 0% | 1 | |||
| bmi | 1 | 0% | 1 |
- Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. 2026 PMID 41606121 PMC13099432 own_data
Archive description
Bacterial communities of patient fecal samples profiled by shotgun metagenomics. Samples for both Melanoma (treated with anti-PD-1 plus anti-CTLA-4 therapy) and NSCLC (treated with anti-PD-1) patients were collected at several time points, including before fecal microbiota transplant (FMT) from healthy donors, and post-FMT (i.e., one week, one month, two months, three months, six months, and one year).
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “Gut microbiota composition of”
- body site study.description · “communities of patient fecal samples profiled by”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN49900585 | age_at_collection_days | 8766.0 | R2 | 0.75 | paper.supp.41591_2025_4186_MOESM1_ESM.pdf[p2t1!Age] | 24 |
| SAMN49900585 | bmi | 24.3 | R2 | 0.75 | paper.supp.41591_2025_4186_MOESM1_ESM.pdf[p2t1!BMI] | 24.3 |
| SAMN49900446 | collection_date | 2021-11-30 | R1 | 0.90 | biosample.attribute:collection_date | 2021-11-30 |
| SAMN49900446 | country | CA | R1 | 0.90 | sample.attr.geo_loc_name | Canada: Quebec |
| SAMN49900567 | health_condition | other_cancer | R1 | 0.70 | sample.name_rule:alias | ONCO_IGR_FMT-101-013-V9 |
| SAMN49900567 | health_condition_detail | FMT: Project description: 'Samples for both Melanoma ... and NSCLC ... patients were collected'; abstract confirms enrollment | R1 | 0.70 | sample.name_rule:alias | ONCO_IGR_FMT-101-013-V9 |
| SAMN49900446 | intervention | fmt | R1 | 0.70 | sample.name_rule:alias | FMT_L_101-001T1 |
| SAMN49900446 | latitude | 45.5117 | R1 | 0.90 | biosample.attribute:lat_lon | 45.5117 N 73.5575 W |
| SAMN49900446 | location_region | Quebec | R1 | 0.85 | biosample.attribute:geo_loc_name | Canada: Quebec |
| SAMN49900446 | longitude | -73.5575 | R1 | 0.90 | biosample.attribute:lat_lon | 45.5117 N 73.5575 W |
| SAMN49900549 | sex | male | R2 | 0.75 | paper.supp.41591_2025_4186_MOESM1_ESM.pdf[p2t1!Sex] | M |
| SAMN49900446 | subject_id | 101-001 | R1 | 0.70 | sample.name_rule:alias | FMT_L_101-001T1 |
| SAMN49900446 | timepoint_label | T1 | R1 | 0.70 | sample.name_rule:source_material_id | T1 |
Sequencing
216 runs over 216 samples · mean 8.74 Gbp per run (median 8.03 Gbp, total 1,886.78 Gbp; 216 runs with a base count) · layout PAIRED 216 · platform ILLUMINA 216 · models Illumina NovaSeq 6000 (216) · 94% of runs with a Sandpiper profile · first public 2025-11-29 – 2026-03-17
Authors (49)
Duttagupta S first · Messaoudene M · Hunter S · Desilets A · Jamal R · Mihalcioiu C · Belkaid W · Marcoux N · Fidelle M · Suissa D · Ponce M · Geiger M · Malo J · Piccinno G · Punčochář M · Filin A · Heidrich V · Rusu D · Mbaye B · Durand S · Ben Aissa I · Puller V · de Lahondès R · Blais N · Tehfe M · Owen S · Bélanger K · Parvathy SN · Shieh B · Raphael J · Lenehan J · Breadner D · Rothenstein J · Rozza N · Maillou J · Nili S · Prifti DK · Pinto F · Armanini F · Kim-Schulze S · Marron TU · Kroemer G · Derosa L · Zitvogel L · Silverman M · Segata N · Maleki Vareki S · Routy B · Elkrief A last
Downloads
PRJNA1289847.csv.gz (8.4 KB) · parquet (82.0 KB) — all 216 samples, every field with route and confidence · PRJNA1289847_determinations.csv.gz (20.3 KB) — 1,938 evidence rows